Transcatheter Tricuspid Valve Repair
StarTric is based in Milan, Italy, with the mission of developing and taking to clinical use an innovative transcatheter structural heart implantable device.
The clinical need addressed is Tricuspid valve regurgitation (TR), and StarTric technology is conceived tobecoming a standard-of-care for the vast majority of TR patients globally.
Tricuspid Regurgitation (TR) is the most common disease of the tricuspid heart valve (TV). It occurs when the tricuspid valve doesn’t close properly and blood flows backward from the right ventricle to the right atrium, reducing the flow to the lungs. TR impacts severely quality of life and survival, by leading to heart failure, atrial fibrillation and other morbidities.
In the US alone, 1.6 million patients are affected by some serious forms of TR (moderate to severe) and
every year, 250K+ new cases of TR are diagnosed,
but only 3% of them receive surgical treatment, while the others remain untreated*.
*Stuge O, Liddicoat J. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardiovasc Surg. 2006 Dec;132(6):1258-61. doi: 10.1016/j.jtcvs.2006.08.049. PMID: 17140937.
StarTric is currently developing a unique transcatether repair implantable device to treat TR.
The technology replicates the Edge-to-Edge "Clover " open surgery technique, developed 15 years ago and performed since then on several hundreds of patients, with positive short and long term outcomes.
For any inquiries, please fill in the following contact form:
BACK TO TOP